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conducted in several Euro-Mediterranean and African countries
disclose impressive similarities in the age and modes of hepatitis
B virus (HBV) transmission and in the prevalence, duration and
outcome of the four phases of the natural history of chronic infec-
tion. Perinatal HBV infection is rare while the vast majority of
chronic infections originate from horizontal HBV transmission
to infants and children. HBeAg loss and seroconversion to anti-
HBe occur in a few years time, usually during the second decade
of life. HBeAg-negative/anti-HBe-positive chronic hepatitis B
(CHB), predominates in these countries being 7–9 times more fre-
quent than HBeAg-positive CHB. The predominance of HBeAg-
negative CHB is largely linked to the molecular characteristics
of HBV genotype D prevailing in European and African countries
of the Mediterranean basin and of genotype E and subgenotype
A1 that prevail in the other parts of Africa. The molecular charac-
teristics of the African subgenotype A1 differ from those of Euro-
pean subgenotype A2 explaining the fact that patients infected
subgenotype A1 demonstrate an earlier loss of HBeAg and sero-
conversion to anti-HBe during the natural course of HBV infection
compared to those infected with subgenotype A2. It is proposed
that the molecular characteristics of HBV genotypes and subge-
notypes prevailing in Euro-Mediterranean and African countries
acting in concert with host and environmental factors largely
determine the natural history of chronic HBV infection and its
signiﬁcant differences from countries of HBV genotype C and B
and of subgenotype Ae predominance. The knowledge of the nat-
ural history of chronic HBV infection in Euro-Mediterranean and
African countries combined with wide screening programs for
prompt recognition and treatment of chronic HBV infection both
in its HBeAg-positive and -negative immune reactive phases can
be expected to increase the efﬁcacy of current and future thera-
peutic strategies.
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E-mail address: hadziyannis@ath.forthnet.grKnowledge of the natural history of chronic hepatitis B virus
(HBV) infection is essential in order to understand why HBV
patients may present with greatly differing clinical, serological,
biochemical and liver histological proﬁles as well as why these
characteristics may remain stable or change signiﬁcantly over
time. Good knowledge of the natural history of the infection
and of the underlying HBV-induced liver disease is also crucial
for the decision to treat or not, of how to treat and how to mon-
itor both treated and untreated patients.
However, the natural history of chronic HBV infection appears
to exhibit signiﬁcant geographical and other differences that may
be linked to respective differences in viral, host, and environmen-
tal factors. The characteristics of chronic HBV infection in the
Mediterranean Basin have hitherto been well described in many
individual countries of this area; however, despite the existence
of numerous common features that differ signiﬁcantly from those
in other geographical areas, a holistic view of its overall natural
history in Euro-Mediterranean and African countries has not
yet been attempted. Even in numerous, excellent reviews of the
overall natural history of HBV infection and of its phases, little
emphasis is given on the particular features prevailing in the
Mediterranean area.
It is the purpose of this article to critically review data on the
natural history of chronic HBV infection in Euro-Mediterranean
and African countries as compared to respective information
derived from other geographical areas and to evaluate the possi-
ble role of viral, host and other factors.
In this review I thought it was necessary to start with a brief
historical account on how the natural history concept has evolved
over the years, followed by a concise review of current knowl-
edge on when and how chronic HBV infection develops and by
a description of the phases in its natural history.Historical view of the natural history of chronic HBV infection
Up to the mid 1960’s nothing was really known on viral hepatitis
B and on its natural history. Then in 1967 the scenery of hepatitis
B opened by the demonstration that a serum protein, the Austra-
lia (Au) antigen, discovered in the early 1960s by Blumberg et al.
[1], was speciﬁcally associated with viral hepatitis type B [2] and
represented the coat protein of HBV itself [3]. Worldwide seroep-
idemiological studies of Au antigen and its antibody, properly11 vol. 55 j 183–191
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renamed to hepatitis B surface antigen (HBsAg) and antibody
(anti-HBs), disclosed in the 1970s that HBV infection is a major
global public health problem with nevertheless signiﬁcant geo-
graphical variations [4,5]. It was also realized that individuals
persistently positive for HBsAg differed in their characteristics
and were therefore divided into two categories of chronic HBV
infection: (a) those with chronic liver disease referred as chronic
hepatitis B (CHB) patients and (b) those with chronic infection,
but without any clinical and biochemical evidence of underlying
liver damage, referred as ‘‘healthy’’ HBsAg carriers [5,6]. Studies
of the surface and core proteins of HBV in the liver by immuno-
histochemical techniques (Fig. 1) offered evidence in support of
this early view that chronic HBV infection consists of two differ-
ent types or subsets of patients, those with and those without
liver disease [7–9]. Then, another HBV protein, the hepatitis B e
antigen (HBeAg) was discovered by Magnius and Espmark [10]
and was added to the scenery of hepatitis B as a marker of HBV
replication.
Testing for serum HBeAg and its antibody (anti-HBe) by a sen-
sitive radioimmunoassay (RIA) developed in 1978, in combina-
tion with liver biochemistries and histology, showed that
HBsAg-positive patients with chronic hepatitis B were HBeAg-
positive while ‘‘healthy’’ HBsAg carriers were HBeAg-negative/
anti-HBe positive [11]. Chronic HBV infection in the above twoFig. 1. Microphotographs of liver histology and of HBsAg and HBcAg expression in t
patient with chronic active HBV liver disease (C and D). There are numerous ground-
loaded with HBsAg as shown by green immunoﬂuorescent staining (B). Hepatitis B core
picture of liver histology and immunohistochemistry of the patient with active
immunoperoxidase staining of HBcAg in the nuclei and cytoplasm of hepatocytes (C). H
184 Journal of Hepatology 201groups was, therefore labeled as ‘‘replicative’’ and ‘‘non-replica-
tive’’, respectively, and on the basis of follow-up data from a
cohort of HBeAg-positive patients, it was proposed that they rep-
resented sequential phases in the natural course of chronic HBV
infection rather than independent types of chronic hepatitis B
[11,12]. It was also assumed and largely accepted that after
HBeAg loss and seroconversion to anti-HBe, HBV becomes practi-
cally inactive. The fact that HBsAg continues to remain detectable
was attributed to its expression and secretion in serum from
HBsAg sequences integrated into the host genome [13–15]. Con-
sistent with this concept was the information obtained by the
application of non-sensitive dot-blot assays measuring serum
HBV DNA with a limit of detection of approximately 1 million
copies/ml.
However, during the same period of the 1980s, studies in
Asian patients revealed (mostly in children and young age
groups) the existence of an early phase in the natural course of
chronic HBV infection [16] during which HBeAg is positive, HBV
DNA levels are very high but aminotransferases and liver histol-
ogy remain nearly normal. This was considered to be an immune
tolerant state and a 3-rather than a 2-phase natural history of
chronic HBV infection was proposed. Concomitantly, the exis-
tence of HBeAg negative CHB was recognized in the Mediterra-
nean area ﬁrst on the basis of immunoﬂuorescence studies [17]he liver of an individual in the inactive HBsAg carrier state (A and B) and of a
glass hepatocytes in the otherwise normal liver of the inactive HBsAg carrier (A),
antigen (HBcAg) expression was completely negative. Completely different is the
chronic hepatitis B showing severe necroinﬂammation, ﬁbrosis and positive
BsAg is also positive in several hepatocytes (D).
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Fig. 2. The proposed natural history of chronic HBV infection (modiﬁed from
Ref. [54]). The takeover of precore HBV mutant strains in the natural history of
primary HBV infection with wild type, HBeAg-positive virus, as proposed by
Brunetto et al. [30], is depicted in the lower part of the ﬁgure.
JOURNAL OF HEPATOLOGYand then by assays of serum HBV DNA [18–20] and was added to
the natural history of chronic HBV infection as a late phase of
HBV reactivation (Fig. 2). The application of sensitive assays for
the measurement of serum HBV DNA by polymerase chain reac-
tion (PCR) methods conﬁrmed the earlier Mediterranean ﬁndings
and the terms ‘‘replicative’’ and ‘‘non-replicative’’ phases were
modiﬁed to ‘‘high’’ and ‘‘low’’ replicative, respectively [15].
Recently, a new scheme of the natural history of chronic HBV
infection has been proposed based not only on the HBeAg/anti-
HBe status but also on host immune activity against the replicat-
ing virus [21–24]When and how chronic HBV infection develops
It is well established now that acute HBV infection may become
chronic at highly variable rates depending on the age and modes
of HBV transmission. The highest rates of transition of an acute
infection to chronic (>80%) have been reported in cases of
materno-fetal and neonatal HBV transmission from HBeAg-
positive mothers [25,26]. Primary HBV infection in infancy and
childhood has been found to become chronic at a much lower rate
(20–30%). After childhood, the rates of transition to chronicity in
otherwise healthy adults have been well documented and shown
to be extremely low, even lower than 1% [27], with the exception
of immunocompromised individuals. The high rates of chronicity
of HBV infection in neonates and toddlers have been largely
attributed to the immaturity of the host immune system of these
very young age groups. Moreover, data from sequencing of the
infecting HBV strains have revealed that the sine qua non prere-
quisite of an acute HBV infection in order to become chronic, is
that the infecting HBV strain be of wild type (wt) in its precore
region [28,29] and, therefore, producing HBeAg. Otherwise, acute
infection will run a self-limited course regardless of the age at itsJournal of Hepatology 201acquisition. It is noteworthy that this knowledge has been
acquired following the discovery of precore HBV mutants in the
Mediterranean area [30,31]. However, since mixtures of wt and
precore mutant HBV strains may also co-circulate in the same
HBeAg-negative individual, it is possible that acute HBV infection
acquired from an HBeAg negative person harboring suchmixtures
of HBV strains may turn out occasionally to become HBeAg-
positive, provided that a precore wt HBV strain from the mixture
becomes selected in the newly infected newborn [28,32]. How-
ever, expression of the HBe protein as a prerequisite for an acute
hepatitis B to become chronic requires the immune tolerance of
the host against HBV. This explains the very high rates of chronic-
ity (90%) of HBV infection in neonates born to HBeAg + mothers
[33], the intermediate rates in children and the extreme rarity
(0.1%) of chronicity in a large numbers of immunocompetent
Greek adults with a well documented diagnosis of primary, acute
hepatitis B after exclusion of patients with acute exacerbations of
chronic HBV infection [28,34].Phases in the natural history of chronic HBV infection
On the basis of information derived from selected research and
review articles [35–48] current views on the natural course of
HBV infection and its phases can be summarized as following:
Once HBV infection has become chronic, its subsequent course
largely consists of four phases of variable duration and outcome
of the underlying liver disease (Fig. 2). All phases have been
linked pathogenetically to the level of HBV replication and the
strength of the host immune reactivity against the replicating
HBV. The ﬁrst two phases are associated with HBeAg seropositiv-
ity while the other two develop after clearance of HBeAg and
development of anti-HBe immunity [49,50]. Loss of HBsAg signals
a most favorable outcome of chronic HBV infection and is gener-
ally regarded as the closest one to cure of the infection. This may
occur spontaneously or can be induced by treatment in any phase
of the natural history of chronic infection at different, however,
rates. Moreover, transition from one to the next phase of chronic-
ity is not recognizable in all patients either because it may not be
an obligatory step in the overall natural course of the infection or
because it is of very short duration.The ﬁrst phase
This phase is considered to represent a state of immune tolerance
of the virus by the host, permitting its replication usually at very
high levels. During this phase, HBeAg is positive, serum HBV DNA
levels are very high, HBV infectivity is high but, as already men-
tioned in the introduction, ALT activity is normal and hepatic his-
tology reveals little if any liver damage. Despite the close link of
this immune tolerant phase to vertical HBV transmission in neo-
nates, such a phase can also occur in horizontal HBV transmission
from HBeAg positive individuals to toddlers but at signiﬁcant
lower rates (20–30%)
The duration of the immune tolerant phase is variable. In
vertical HBV transmission from HBeAg positive mothers it may
last for more than 3 decades while under other conditions as in
horizontal HBV spread among children, it appears to be very
short and hardly recognizable [15]. The possible role of the infect-
ing HBV genotypes, racial, nutritional or environmental factors is
discussed in a subsequent part of this review.1 vol. 55 j 183–191 185
ALT
(U/L)
ALT
(U/L)
0
100
200
300
400
500
600
700
800
900
1000
1100
1200
400
500
600
A
B
Anti-HBe (+)HBeAg (+)
HBeAg-/Anti-HBe (+)
1978 1982 1986 1990 1994 1998 2002
Review
The second phase
The initial immune tolerance phase of HBeAg-positive HBV infec-
tion leads to a second phase of immune reactivity against HBV
that is implicated pathogenetically in the development of liver
necroinﬂammation and ﬁbrosis. In clinical practice, this phase
is referred as HBeAg-positive CHB but the terms immune reac-
tive, immune active or HBeAg clearance phase are also applied.
Serum continues to be HBeAg-positive, HBV DNA levels are usu-
ally high but variable, levels of ALT are increased and liver histol-
ogy reveals necroinﬂammation with variable stages of ﬁbrosis.
The severity, duration and outcome of this phase and of the
underlying liver damage are variable. The annual rate of sponta-
neous HBeAg clearance in this phase is also variable ranging from
3% to 12% and increases by 2–3 times with interferon alpha (IFN-
a) treatment. The phase of HBeAg–positive CHB may end not only
in HBeAg seroconversion but also in HBsAg clearance and sero-
conversion to anti-HBs [51–53]. However, in a number of patients
HBV replication continues despite HBeAg loss and the develop-
ment of anti-HBe antibodies.0
100
200
300
1978 1982 1986 1990 1994 1998 2002
Fig. 3. Two examples of HBeAg-negative/anti-HBe-positive chronic hepatitis B
manifested following the inactive HBsAg carrier state of several years
duration with normal liver chemistries and positive anti-HBe. In the upper
part of the ﬁgure anti-HBe-positive liver disease is shown to developed after loss
of HBeAg while in the example of the patient depicted in the lower part there was
no evidence or history for such a previous HBeAg-positive immune reactive phase
phase. Courtesy of Prof. S.J. Hadziyannis.The third phase
Although the previous phase of immune reactivity against HBV
may have unfavorable outcomes with progression of the underly-
ing liver necroinﬂammation and ﬁbrosis to cirrhosis and even to
development of hepatocellular carcinoma (HCC) and death, it lar-
gely terminates sooner or later in HBeAg clearance and transition
to a third phase during which anti-HBe is positive, there is little
residual viral replication and liver histology is essentially normal,
except for the presence of ‘‘ground-glass’’ hepatocytes harboring
cytoplasmic HBsAg, mainly attributed, as stated, to its expression
from HBV DNA sequences integrated into the genome of hepato-
cytes (Fig. 1). This third phase actually corresponds to the so
called ‘‘inactive HBsAg carrier state’’.The reactivation phase
The previous phase of anti-HBe-positive inactive HBsAg carrier
state is not always equivalent with a permanent termination of
replication and of HBV-induced chronic liver damage. Although
the majority of patients remain for life time in an inactive carrier
state and a number of them (around 2% per year) may lose HBsAg
and enjoy a complete recovery, others retain or redevelop over
time signiﬁcant HBV replication and progressive liver damage
[18,19,30,31,39,54]. This state of HBV-induced liver damage has
been ﬁrst referred to as ‘‘HBeAg-negative/anti-HBe positive
chronic hepatitis B’’ and is considered by most authors as a fourth
or reactivation phase in the natural course of chronic HBV infec-
tion (Fig. 2). Two representative examples of development of
HBeAg-negative CHB after several years of inactivity with normal
liver chemistries and anti-HBe positivity are depicted in Fig. 3.
HBeAg-negative/anti-HBe-positive CHB being usually a late phase
in the course of chronic HBV infection is manifested among rela-
tively older age groups of patients with a mean age difference
from HBeAg-positive CHB of 10 or more years [55]. Its prevalence,
initially thought to be low and geographically restricted, has sub-
sequently been reported to increase and spread worldwide. Cur-
rently, HBeAg-negative CHB represents the far commonest type186 Journal of Hepatology 201of chronic hepatitis B particularly in European, African and Mid-
dle East countries of the Mediterranean Basin [38,56,57].
As stated in the introduction, HBeAg-negative CHB has been
ﬁrst recognized in 1981 while precore HBV mutants with a
G1896A mutation resulting in a novel precore translational stop
codon at position 28, preventing HBeAg formation without affect-
ing HBV replication were discovered in 1989. With these molec-
ular/biological ﬁndings a convincing answer was given to the
burning questions raised by several hepatitis experts of how it
is possible for HBV to go on replicating or to reactivate and
how can CHB develop despite the loss of HBeAg and in the pres-
ence of anti-HBe immunity. In recent reviews [15,38,56] it is
clearly stated that understanding the molecular basis of HBV rep-
lication in HBeAg-negative patients represents a major milestone
in hepatitis B research and in revealing its natural history. Never-
theless, it was only in the 2000s with a delay of two decades, that
HBeAg-negative CHB was formally accepted as a phase in the nat-
ural course of chronic infection with the wt HBV [22,24].Distinct characteristics of the natural history of chronic HBV
infection in Euro-Mediterranean and African countries
As stated above, in European and African countries of the Medi-
terranean Area, chronic HBV infection and its natural history
share a number of features, largely differing from the respective1 vol. 55 j 183–191
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Fig. 4. Geographical map displaying the levels of HBV endemicity in the world and the areas of predominance of the various HBV genotypes. The overall level of HBV
endemicity in the Mediterranean basin in this map is intermediate but differs signiﬁcantly from country to country. In the Euro-Mediterranean countries current median
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JOURNAL OF HEPATOLOGYones prevailing in other geographical areas. These can be summa-
rized as following:
Vertical transmission in the neonatal period is rare in Euro-
Mediterranean countries and all over Africa. The vast majority
of chronic HBV infections are acquired horizontally in childhood
and are associated with much shorter duration of the ﬁrst two
phases of the natural history of chronic HBV infection. This is at
variance from what has been observed in Southeast Asia, where
primary HBV infection is frequent not only in neonates but also
in infants and children, although in both groups the cumulative
duration of the two HBeAg-positive phases is much longer. The
annual HBeAg seroconversion rate in South-East Asia is 2% in
the ﬁrst 3 years of life increasing to 4–5% in older children.
Almost 90% of infected toddlers still remain HBeAg positive up
to the age of 15 years.
In contrast, in Euro-Mediterranean and African countries only
20–30% of early childhood infections become chronic and only
10% of such chronic infection continue to remain HBeAg-positive
during adolescence. The great majority lose HBeAg quickly, at an
annual rate of 14–16% [58]. Thus, by the second decade of their
life the majority of patients are already HBeAg-negative/anti-
HBe-positive [58–60]. These geographical differences in the nat-
ural history of chronic HBV infection are illustrated in Fig. 5. It
is obvious, that in the Euro-Mediterranean area only few women
remain HBeAg positive during their reproductive age and this
observation largely explains the rarity of perinatal HBV transmis-
sion in the same geographical area.
Not only the initial immune tolerant phase but also the subse-
quent immune active phase of HBeAg clearance (Fig. 2) are shortJournal of Hepatology 201and usually non-recognizable in patients from countries of the
Mediterranean Basin (37–39) and Africa. Moreover, the rates of
development of advanced liver disease, cirrhosis and HCC in
HBeAg-positive patients are signiﬁcantly lower compared to Asi-
atic and other countries, probably because of its shorter duration1 vol. 55 j 183–191 187
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[38]. The third phase of the inactive HBsAg carrier state with
immune control of the infection is usually reached during adoles-
cence being in contrast to the much older age of the respective
phase in other countries particularly from Asia.
In the Euro-Mediterranean and African area the great majority
(>85%) of patients with biochemically and histologically active
disease are HBeAg-negative whereas in Asia, North Europe and
the USA, HBeAg-positive CHB predominates. The mean age of
patients with HBeAg-negative CHB is much older compared to
the age of HBeAg-positive ones in the same area [54,55]. These
age data taken together with the short duration in the Mediterra-
nean area of the immune reactive HBeAg-positive phase, suggest
that the development of HBeAg-negative CHB is largely linked to
the reactivation of HBV in ‘‘inactive’’ HBsAg carriers rather than
with an ongoing HBV replication in continuation of the second
phase of HBeAg-positive CHB patients, despite the loss of HBeAg
and seroconversion to anti-HBe [38,39,54,55]. The frequency of
cirrhosis and of HCC are quite high in HBeAg-negative CHB
patients and increase signiﬁcantly with their age [38,61]. In long
term follow-up studies of Asian patients, it has recently been
reported that the older the age at spontaneous HBeAg serocon-
version, the higher are the rates of development of HBeAg-nega-
tive CHB, of cirrhosis and of HCC. Thus, in patients who lost
HBeAg after the age of 40 years, the 15 year cumulative incidence
of HBeAg-negative CHB, of cirrhosis and HCC reached 66.7%,
42.9% and 7.7%, respectively [62].
The development of HCC in younger age groups of HBsAg-
positive HBeAg-negative patients in the absence of cirrhosis doc-
umented in several areas of Africa particularly in Sub-Saharan
countries [59,61] will be discussed in the context of implicated
factors particularly of HBV subgenotypes.
Finally, the annual rates of spontaneous HBsAg clearance in
the Mediterranean basin appear to be close to 1% in childhood
and adolescence [58] and to increase to 1.5–2.0% in older age
groups [38,63]. These rates appear to be signiﬁcantly higher com-
pared to those reported in countries of Southeast Asia and of
other geographical areas. However, the annual rates of HBsAg
clearance in these countries may have been underestimated since
in more recent studies of longer follow-up extending to >20 years
after HBeAg seroconversion, the HBsAg clearance rate has been
found to increase approximately to 2% [64].Implicated factors
A number of variables appear to be pathogenetically implicated
in the evolution of the natural history of chronic HBV infection
in Mediterranean and African countries.
Level of HBV endemicity
It is assumed that high levels of HBV endemicity in a community
correlates with a higher frequency of exposure to acute (primary)
HBV infection in early life which has the effect of determining the
rates of development of chronic HBV infection as well several
aspects of its natural history. This does not appear to be the case
in European, African as well as in Near and Middle East countries
of the Mediterranean Basin. Although the level of HBV endemicity
is intermediate (varying between 2% and 8%, Fig. 2); regions and
foci of high, as well as, of low HBV endemicity have been identi-
ﬁed within the same country. Furthermore, while a signiﬁcant188 Journal of Hepatology 201decrease in the prevalence of HBsAg at least in certain countries
like Greece, Italy, and Spain has occurred over the years, in many
areas of Africa, HBV endemicity remains high. Despite these vari-
ations in HBV endemicity between Euro-Mediterranean and Afri-
can regions and countries, the overall features of the natural
history of chronic HBV infection are strikingly similar: HBV infec-
tion of neonates is rare, primary infection with transition to chro-
nicity is restricted to infancy and childhood; and is followed by
early loss of HBeAg and by striking predominance of anti-HBe-
positive CHB. This is true also for the high HBV endemicity areas
of Africa except for the development of HCC at a much younger
age [59,61].
Although the socioeconomic and hygiene level, local condi-
tions and habits of the studied populations as well as genetic
and environmental factors may also play a role, it is now becom-
ing evident that the natural history of chronic HBV infection is
mainly determined by viral factors. HBV genotypes, sub-geno-
types and speciﬁc mutations of the HBV genome are currently
implicated for similarities and differences in its natural history
and the development of severe chronic liver disease and particu-
larly of HCC.
Age and modes of viral transmission
The age at acquisition of hepatitis B and its modes of transmission
have already been discussed. However it is important to stress
that the use of non-disposable needles and syringes for vaccina-
tion and other purposes has been implicated in Greece, Italy and
in African countries. Moreover contrary to the situation in South
East Asia where vertical transmission from HBeAg positive moth-
ers to neonates predominated, at least in the pre-vaccination era
[61], this has not been the case of HBV spread in the Mediterra-
nean Basin as well as all over Africa (66). This can be explained
by the fact that few of HBV infected mothers fulﬁll the prerequi-
site for vertical HBV transmission of HBeAg positivity. Several
large epidemiological studies in the Mediterranean basin and
Africa have showed that <5% of HBsAg positive young adults and
of women in their reproductive age are HBeAg positive [59,60].
HBV genotypes
From 2000 and on, HBV genotypes and subgenotypes have
attracted a lot of clinical and research interest and are currently
considered as determinants and/or predictors of the natural his-
tory of HBV infection, the severity of HBV-induced liver disease
and of the risk of HCC development. In this context a number
of relevant clinical and molecular studies [59,65–68] have been
recently reviewed [69].
In the Mediterranean Basin there is an impressive overall pre-
dominance of HBV genotype D (Fig. 4) that also extends to other
neighboring countries [70]. In the early 1970s, when HBV geno-
types had not yet been identiﬁed, Hadziyannis and LeBouvier
[69] conducted a large study of HBsAg subtypes in acute and
chronic HBV infection in Greece and found a higher than 90% pre-
dominance of subtypes ayw2 and ayw3. These serotypes are now
known to correspond to HBV genotype D. Genotype D predomi-
nance all over the Mediterranean area (Fig. 4) has been found
in some regions to account for more than 80% and even >90% of
HBV infections [59,71].
The other HBsAg serotype that has been detected in the Med-
iterranean area in the 1970s is adw and corresponds to genotype1 vol. 55 j 183–191
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A. In Greece it accounted for approximately 5% of the overall
cases of HBV infection and this low prevalence has remained
unchanged over the years [72]. Genotype A prevails in some
countries of North Europe and in South Africa.
In the Mediterranean and surrounding countries of high geno-
type D predominance, there is a similarly impressive predomi-
nance of HBeAg-negative precore mutant CHB. A similar
association exists between HBeAg-negative CHB and genotype E
in Central and West African countries. The molecular characteris-
tics of HBV genotypes D and E that determine HBeAg loss are the
same but different from those of genotype A and of its subgeno-
types [59,68,71].
The nucleotide harbored at position 1858 in genotypes D and
E is T, and the G1896A mutation, which develops during the
course of chronic HBV infection where it prevents the formation
of HBeAg, creates a strong T-A bond that stabilizes the stem of the
epsilon (e) encapsidation signal of the virus [55]. This is actually
true for all HBV genotypes with T at position 1858, while in the
case of HBV genotype A the nucleotide harbored at 1858 is C,
and this precludes the development of a stable precore transla-
tional stop codon unless a C1858T mutation also develops. There-
fore, it is not surprising that HBeAg-negative CHB rarely, if ever,
develops in infections with HBV genotype A at least when a Euro-
pean strain of genotype A is involved [72].
In contrast to the Mediterranean area and West and Central
Africa where genotypes D and E prevail, (Fig. 4) genotype A is
the predominant genotype in sub-Saharan countries and South
Africa [59]. In these areas HBeAg loss occurs early in the natural
course of HBV infection and HCC develops in younger age groups
even in the absence of cirrhosis [61]. These geographical varia-
tions seem to be explained by differences in the molecular char-
acteristics of HBV genotype A of African and European strains
compared to genotype D [59,68,71].
HBV subgenotypes
HBV genotypes differ by >8% in the overall sequence of the HBV
genome and by >4% in the sequences of the surface gene
[24,73,74]. Geographical similarities in the prevailing HBV geno-
types may extend or not to their subgenotypes. In the case of
genotype D, the same subgenotypes appear to prevail in the Med-
iterranean area and the surrounding countries. On the other
hand, in the case of genotype A there are signiﬁcant differences
between subgenotype A2 (or Ae) that prevails in Europe and sub-
genotype A1 (or Aa) that predominates in Africa. In fact the Afri-
can subgenotype A1 has molecular characteristics that appear to
determine early HBeAg clearance by prevention of its formation
both at the transcriptional and translational level; while in infec-
tion with the European subgenotype A2, HBeAg loss is linked to
development of mutations acting only at the transcriptional level.
Such mutations are neither stable nor associated with the devel-
opment of anti-HBe positive CHB [51]. Thus, data on HBV geno-
types and subgenotypes in the geographical area of the
Mediterranean basin extending to those in the surrounding coun-
tries and in Central and South Africa, may account for and explain
a number of associated similarities and differences in the natural
course and clinical outcomes of chronic HBV infection.
The African subgenotype A1 is found in S. Africa, Malawi,
Uganda, Tanzania, Somalia and Yemen [26,59,71]. Compared to
the European Ae, Aa is much less frequently HBeAg+ (33% vs
67%) and is associated with lower HBV DNA levels (3.5 vs 6.1Journal of Hepatology 201log copies/ml); moreover, its characteristics at the molecular
level are compatible with the observed early and durable HBeAg
loss and seroconversion to anti-HBe [67,68]. It harbors a double
substitution at T1809 and T1812 (100% and 96%) upstream of
the precore initiation codon which interferes with the translation
of HBeAg. This substitution has not been detected in any of 57 Ae
isolates. Furthermore, the hepatocarcinogenetic potential of the
African subgenotype A1 appears to be greater than that of other
genotypes in the same geographical area. Thus, in Sub-Saharan
Bantu speaking Africans, HBV-related HCC has been found to be
almost entirely attributable to subgenotype A1 [66,75,76]. In
recent studies several mutations affecting the X gene of HBV
identiﬁed in subgenotype A1 have been implicated in the early
development of HCC in Africa. Moreover, since the African HBV
subgenotype A1 has also been exported to other geographical
areas and has already been detected in European countries (Italy,
Spain, France) it is intriguing to evaluate whether the outcome of
chronic HBV infection with HBV genotype A1 vs genotype A2 dif-
fers under the same nutritional and environmental factors.
On the basis of the above data many more studies on the
molecular and biological aspects of HBV and its genotypes, sub-
genotypes and the development of mutations in the course of
HBV infection, are recommendable in appropriate populations
and cohorts of patients [45].Conclusions and perspectives
The natural history of chronic HBV infection in Euro-Mediterra-
nean and African countries is characterized by many similarities
in the evolution, duration and outcome of its phases. The Medi-
terranean characteristics of its natural course differ signiﬁcantly
from the respective ones in other geographical areas of the world.
It is now becoming obvious that similarities and differences in
the natural history of HBV infection are largely linked to the
molecular characteristics of the prevailing HBV genotypes and
subgenotypes. Host and environmental factors may also contrib-
ute to a shorter or longer natural history and to the rate of devel-
opment and severity of HBV-induced chronic liver disease
particularly HCC. Appropriate long term studies are needed to
clarify the speciﬁc role played by numerous viral, host, environ-
mental and other factors and their interplay in the natural course
of chronic hepatitis B and in the rate and time of development of
severe liver disease and HCC. Relevant information is expected to
determine the best monitoring strategies to be applied in clinical
practice aiming at early recognition and treatment.
Despite a signiﬁcant progress achieved in the understanding
of the natural history of chronic HBV infection and of the devel-
opment and progression of HBV-induced liver disease, the
involved molecular pathogenetic mechanisms and the role
played by host immune, environmental and other pressure in
the adaptive evolution of HBV remain largely unknown. Acquir-
ing such knowledge would be particularly important in relation
to the high hepatocarcinogenetic potential of HBV subgenotypes
prevailing in several parts of Africa. Once the mechanisms oper-
ating at the molecular level during the various phases of the nat-
ural course of chronic HBV infection have been unraveled, it is to
be expected that new therapeutic strategies will follow; these
will aim at not only obtaining sustained biochemical and virolog-
ical responses but also to cure the infection regardless of the
phase in its natural history. However even with existing therapies1 vol. 55 j 183–191 189
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higher response rates could be expected both in HBeAg-positive
and HBeAg-negative chronic hepatitis B patients, provided that
the underlying liver disease has not progressed to advanced
stages. In this context, good knowledge of its overall natural his-
tory in each geographical area and of the onset and duration of its
phases can contribute to the design of appropriate and practically
applicable programs aiming at early recognition and treatment of
HBV-induced chronic liver disease.
Key Points  
Contrary to Southeast Asia, vertical HBV transmission 
is rare in the Mediterranean basin where horizontal 
transmission in early childhood is the predominant 
mode of HBV transmission, accounting for the vast 
majority of chronic HBV infections (>90%) 
In Euro-Mediterranean and African countries, the 
duration of the HBeAg positive phase of chronic HBV 
infection is short (compared to Southeast Asia 
countries), and thus during the second decade of life 
the majority of HBsAg positive patients become 
HBeAg negative/anti-HBe positive (80-90%) 
Geographical differences in the natural history of 
chronic HBV infection are largely determined by the 
molecular characteristics of the prevailing HBV 
genotypes, subgenotypes and their selected mutants 
Genotype D HBV infection that prevails in the 
Mediterranean Basin (>90%) and its selected precore 
stop codon mutants that prevent HBeAg production, 
is associated with a high predominance of HBeAg-
negative chronic hepatitis B in this area, leading to 
cirrhosis and hepatocellular carcinoma. Conﬂict of interest
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